Comments to FDA: Internal Analgesis, Antipyretic, and Antirheumatic Products for OTC Human Use

CHPA comments on the proposed rule, which proposes new warning and other labeling requirements for internal analgesic, antipyretic, and antirheumatic OTC drug products.